N/A N=140 A Study to Determine the Effects of Adding an Experimental Device With Mouthrinse to Oral Care Regimen
Gingivitis
Primary: Interproximal Mean Plaque Index at Week 4 — 2.674; 2.213; 2.005 Units on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=60 Characterizing and Predicting Drug Effects on Cognition
Cognitive Deficits
Primary: Change From Baseline in COWA Unique Word Count — -0.407725385; -0.425898667; -0.412534118; -0.108298333 Word Count
Phase 2 N=122 A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Acute GVHD
Primary: Percentage of Participants With Complete or Partial Response (CR/PR) to Acute GVHD Treatment — 35; 46; 19; 17 Participants
Phase 2 N=4 TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) — 0 Participants
Phase 3 N=10 The Bihormonal iLet Bionic Pancreas Feasibility Study
Type 1 Diabetes Mellitus
Primary: Percentage of Time That Valid CGM Glucose Readings Are Captured by the iLet Bionic Pancreas — 89.2; 91.0 percentage of time
Phase 4 N=100 A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania
Poliomyelitis
Primary: SAEs and Severe AEs — 0; 0 Participants — p=0.05
Phase 2 N=364 Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
Knee Osteoarthritis
Primary: Primary Endpoint: WOMAC Pain Score (Likert Scale Version) at 4 Weeks — 8.08; 6.73 units on a scale
Phase 2 N=27 A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
AL Amyloidosis
Primary: Assessing Dose-limiting Toxicity to Determine Maximal Tolerated Dosage at 2 Milligram Dose — 0 Participants
Phase 3 N=189 Progesterone for Perimenopausal Night Sweats
Hot Flushes · Night Sweats
Primary: Vasomotor Symptoms (VMS)/ VMS Score - at 12 Weeks — 5.5; 7.1 Units of Vasomotor Symptom Score
Phase 3 N=1,151 Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
Acute Ischemic Stroke · Diabetes · Hyperglycemia
Primary: Number of Participants With a Favorable Modified Rankin Scale (Yes/No) — 119; 123 Participants — p=0.55
Phase 3 N=2,106 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.
Anemia
Primary: Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 — 0.77; 0.68 g/dL — p=<0.001
N/A N=184 Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
Alcoholism · Substance-related Disorders · Dual Diagnosis
Primary: Standard Ethanol Content Units (SECs) Baseline — 179.9; 190.1 Standard Ethanol Content Unit
N/A N=55 Clinical Evaluation of FLACS With Combination of LenSx® and Centurion®
Cataract
Primary: Cumulative Dissipated Energy (CDE) — 0.213; 1.718 unitless — p=<0.0001
Phase 2 N=48 Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) — 0; 0; 0; 0 Participants
Phase 2 N=81 High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
Lymphoma
Primary: Event-free Survival (EFS) of Patients — 51 Participants